Yes, but I am starting to wonder whether their doing a dozen things in parallel (which of course is good for increasing the intrinsic value of the company) somewhat interferes with their top-priority, the BLA submission: unless granted breakthrough designation, due to their negligence regarding 700mg stability data, there will be another 1.5 months delay that costs about 7.5m, or about 20m more shares via dilution. If you are that low on cash and at .39 cents, you simply can't allow yourself to make such a mistake. Will there be a "performance malus" now for BOD and management? - don't think so.

But of course still very excited now for mid/end of October!